Dr. Miguel Medina earned his PhD in Biochemistry and Molecular Biology from the Universidad Autónoma of Madrid. After a few years of postdoctoral work in virology and animal health, he became interested in the field of neuroscience and human pathology and since then he has acquired extensive research experience in the study of the molecular basis of neurodegenerative diseases.
Dr. Medina has worked in various academic centers of maximum scientific prestige, having been a postdoctoral fellow at the Center of Molecular Biology “Severo Ochoa” in Madrid (1993-1995), and then at the Center for Neurologic Diseases, Harvard Medical School in Boston (1996-2001), where he was appointed as a Harvard Junior Faculty, as well as an independent Senior Scientist at the Cavalieri Ottolenghi Scientific Institute of the University of Turin (2001-2003). Dr. Medina has also carried out postdoctoral stays in the United Kingdom (1989-1990) and The Netherlands (1990, 1991).
From 2003 until 2007 Dr. Medina was recruited to head the Drug Discovery Department of the Spanish biopharmaceutical company Neuropharma S.A. (later on Noscira S.A.), where he built from scratch and spearheaded a solid scientific platform for searching, identifying and isolating compounds as potential therapeutic agents for the treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD). In November 2007, he became Research Director at Noscira, leading a research team that moved two novel compounds from early discovery into phase I and phase II proof of concept clinical trials for AD and progressive supranuclear palsy (PSP). During the 9 years spent in industry, Dr. Medina was able to raise over 10M€ in public research grants and loans (national and international) as Principal Investigator. Also he has participated very actively in defining short- and long-term scientific objectives of the company as well as in defining, following-up and critically evaluating the research objectives of the company, being responsible for managing a multidisciplinary research team of up to 42 people budget management (up to 3.8 M€ per year), staff recruitment, resources assignment and team management.
Dr. Medina was also responsible for coordinating the Scientific Advisory Board annual meetings and internationalization, innovation, dissemination, and transfer of knowledge activities. In March 2012 he was appointed as Deputy Scientific Director of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases), where he combine R&D management activities with active translational research efforts, especially as PI of the Vallecas project, a multi-year longitudinal study for early detection of Alzheimer’s disease. Dr. Miguel Medina is the Spanish representative in the COEN (International Network of Centres of Excellence in Neurodegeneration) Oversight Group, and serve as a member of the External Scientific Advisory Board of the CIEN Foundation and the Ethics Advisory Committee of the Human Brain Project.
He has been part of the Technical Committee of the Strategy for Neurodegenerative Diseases of the National Health System and is also a member of the editorial boards of the international journals Recent Patents on Biothecnology, Recents Patents on CNS Drug Discovery, Journal of Bioequivalence and Bioavailability, Aging & Neurodegeneration, and Journal of Alzheimer’s disease.
Dr. Medina has authored over 80 peer-reviewed scientific publications (H-index=34, >3,700 citations) and is listed as co-inventor of 25 patents.
Aging, Neurodegeneration, Alzheimer disease, Neurology, Neuroimaging, Neuropathology, Genetics, Biochemistry
The Neurological Diseases Research Center Foundation (CIEN Foundation) is a non-profit foundation belonging to the public sector, of scope and state competence. Currently, it depends on the Ministry of Economy, Industry and Competitiveness, through the Carlos III Health Institute. Its main objective is to support, promote and coordinate research in neurodegenerative diseases, uniting and coordinating the efforts of leading Spanish research groups.
Since its establishment, the CIEN Foundation manages the Alzheimer Project Research Unit (UIPA), created by the Queen Sofia Foundation, with which it shares the objective of addressing Alzheimer’s disease from an integral perspective, in which research is one of the fundamental pillars.
The main exponent of this integrative model is the Alzheimer Center Reina Sofía Foundation, whose Research Unit is provided by the Queen Sofia Foundation to the CIEN Foundation. In this center, since its inauguration in 2007, Alzheimer’s disease is addressed from three simultaneous angles: research, training and healthcare service for patients.